T cell assays
Robust In vitro assays are curial for characterising drug candidates (biologics or small molecules) modulating immune responses. At BioMedha, we have on-site blood donor panel and collect whole blood from consented healthy donors on the day of experimental setup. We have developed various T cell assays supporting client projects.
T cell activation (Th-1, Th-2 and Th-17 cytokine secretion)
Figure-1: Activation of Th-1, Th-2 and Th-17 cytokine secretion. Freshly isolated human PBMCs from healthy donor were treated with combination of anti-CD3 (plate bound) and anti-CD8 (soluble) for 48 hours before harvesting cell supernatant for cytokine analysis.
T cell proliferation
Figure-2: Fresh PBMCs treated with plate bound anti-CD3 and soluble anti-CD8 for 5 days. Cell proliferation measured by ATPlite reagent.
T cell killing
Figure-3: Anti-CD3/CD19 bispecific T cell engager (BiTE) blinatumomab induces (24 hours treatment) cytotoxicity of CD3+ T cells against Daudi B lymphoblast cells at various E:T ratios.
IL-22 secretion
Figure-4: Freshly isolated T cells from three different healthy donors were treated with ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator for 72 hours before harvesting supernatant for IL-22 levels analysis.
Phenotyping
Figure-5: T cell phenotyping
T cell exhaustion
Figure-6: Fresh PBMCs treated with Staphylococcal enterotoxin B (SEB) for 72 hours before harvesting supernatant. Cells washed and resuspended into the media and incubated for 24 hours before harvesting supernatant for INFg levels analysis.